Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Advisors Asset Management Inc.

Advisors Asset Management Inc. grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 41.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,226 shares of the company’s stock after acquiring an additional 14,992 shares during the quarter. Advisors Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $728,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of TAK. Van ECK Associates Corp raised its holdings in shares of Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after buying an additional 356,069 shares during the last quarter. Creative Planning grew its stake in Takeda Pharmaceutical by 46.3% during the 3rd quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after purchasing an additional 49,871 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Takeda Pharmaceutical by 153.7% in the second quarter. AQR Capital Management LLC now owns 90,013 shares of the company’s stock valued at $1,165,000 after purchasing an additional 54,539 shares during the period. Manning & Napier Advisors LLC purchased a new position in shares of Takeda Pharmaceutical in the second quarter worth about $4,098,000. Finally, Hantz Financial Services Inc. acquired a new stake in shares of Takeda Pharmaceutical during the second quarter worth about $2,843,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $13.44 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The company’s 50 day moving average is $14.05 and its 200 day moving average is $13.84. The company has a market cap of $42.76 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 0.25 and a beta of 0.54.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.